Literature DB >> 17900775

Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.

Vincenzo Villari1, Paola Rocca, Valeria Fonzo, Cristiana Montemagni, Pasquale Pandullo, Filippo Bogetto.   

Abstract

PURPOSE: Acute agitation is a common presentation in emergency departments and is often secondary to an underlying psychotic condition. The aim of this study was to compare the effectiveness of three second generation antipsychotics (risperidone, olanzapine, quetiapine) versus haloperidol in the treatment of psychotic agitation for up to 72 h. GENERAL
METHODS: We recruited 101 patients with acute psychosis who were admitted at the Mental Health Department 1 South of Turin, Psychiatric Emergency Service of San Giovanni Battista Hospital, from June 2004 to June 2005.
FINDINGS: Aggressive behavior, as measured by Modified Overt Aggression Scale and Hostility-suspiciousness factor derived from the Brief Psychiatric Rating Scale, significantly improved in all groups, with no significant between-group differences. Extrapyramidal symptoms were more common in haloperidol treated patients compared with patients receiving risperidone, olanzapine or quetiapine.
CONCLUSIONS: Our results show that in the clinical practice setting of emergency psychiatry olanzapine, risperidone, quetiapine are as effective as haloperidol and better tolerated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17900775     DOI: 10.1016/j.pnpbp.2007.09.007

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  8 in total

1.  Organisational interventions for preventing and minimising aggression directed towards healthcare workers by patients and patient advocates.

Authors:  Evelien Spelten; Brodie Thomas; Peter F O'Meara; Brian J Maguire; Deirdre FitzGerald; Stephen J Begg
Journal:  Cochrane Database Syst Rev       Date:  2020-04-29

Review 2.  Pharmacological management of acute and persistent aggression in forensic psychiatry settings.

Authors:  Leslie Citrome; Jan Volavka
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

3.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

Review 4.  [Pharmacotherapy of psychiatric acute and emergency situations: General principles].

Authors:  T Messer; F-G Pajonk; M J Müller
Journal:  Nervenarzt       Date:  2015-09       Impact factor: 1.214

5.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

Review 6.  Management of Violence and Aggression in Emergency Environment; a Narrative Review of 200 Related Articles.

Authors:  Maryam Ziaei; Ali Massoudifar; Ali Rajabpour-Sanati; Ali-Mohammad Pourbagher-Shahri; Ali Abdolrazaghnejad
Journal:  Adv J Emerg Med       Date:  2018-11-29

7.  Effects of quetiapine and olanzapine in patients with psychosis and violent behavior: a pilot randomized, open-label, comparative study.

Authors:  Gabriella Gobbi; Stefano Comai; Guy Debonnel
Journal:  Neuropsychiatr Dis Treat       Date:  2014-05-07       Impact factor: 2.570

Review 8.  Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation).

Authors:  Edoardo G Ostinelli; Mohsin Hussein; Uzair Ahmed; Faiz-Ur Rehman; Krista Miramontes; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2018-04-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.